Clovis Oncology (CLVS) Announces Submission of Rociletinib NDA to U.S. FDA for EGFR NSCLC
Tweet Send to a Friend
Clovis Oncology (NASDAQ: CLVS) announced that it has submitted its New Drug Application (NDA) regulatory filing to the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
